Survodutide vs Retatrutide: Key Differences

Survodutide vs Retatrutide: Key Differences. Compare survodutide and retatrutide mechanisms, clinical evidence, MASH research, safety limits, and investigational status. Key Takeaways Survodutide is a dual agonist: It activates GLP-1 and glucagon receptors. Retatrutide is a triple agonist: It activates GLP-1, GIP, and glucagon receptors. Both remain investigational: Neither compound is FDA-approved or an approved treatment as of August 2026. The evidence cannot be treated as head-to-head: Separate trials used different populations, durations, endpoints, and analysis plans. Survodutide has the more developed liver-specific record: Its program includes biopsy-based MASH research and Phase 3 MASLD data. Tolerability remains a major limitation: Gastrointestinal adverse events were common in both development programs. Survodutide vs retatrutide is a comparison between two investigational multi-receptor peptides, not two approved medicines. Their most important difference is receptor coverage: survodutide combines GLP-1 and glucagon receptor agonism, while retatrutide adds GIP receptor agonism to that same two-receptor foundation. That extra receptor does not make the evidence directly comparable or establish that one compound is better. This research overview separates mechanism, clinical-trial findings, liver-focused research, tolerability, and regulatory status without providing medical advice, dosing instructions, or a product recommendation. Survodutide vs Retatrutide at a Glance Survodutide, also known by the development code BI 456906, is being developed by Boehringer Ingelheim under a collaboration that originated with Zealand Pharma. Retatrutide, also known as LY3437943, is being developed by Eli Lilly. Both programs study metabolic disease, but the compounds are chemically distinct and belong to different clinical-development programs. The comparison is most useful as a map of research strategies. Survodutide asks what a GLP-1/glucagon dual agonist can do across obesity and liver-disease endpoints. Retatrutide asks whether adding GIP activity to GLP-1 and glucagon can broaden the metabolic response. Neither question has been answered by a direct survodutide-versus-retatrutide trial. Feature Survodutide Retatrutide Receptor profile GLP-1 + glucagon GLP-1 + GIP + glucagon Development code BI 456906 LY3437943 Developer Boehringer Ingelheim / Zealand Pharma origin Eli Lilly Liver-research emphasis Dedicated MASH and MASLD trials Liver outcomes under study within a broader program U.S. regulatory status Investigational; not FDA-approved Investigational; not FDA-approved How Survodutide's Dual-Receptor Mechanism Works Survodutide activates the GLP-1 receptor and the glucagon receptor. GLP-1 receptor activity is associated with glucose-dependent insulin signaling, glucagon regulation, gastric emptying, and appetite-related pathways. The glucagon component is being studied for its effects on energy metabolism and liver biology. Those mechanisms are research targets, not proof of an individual clinical outcome. The design intentionally balances two signals that can pull metabolism in different directions. GLP-1 activity supplies the incretin component, while glucagon-receptor activity may influence energy expenditure, lipid handling, and hepatic pathways. The scientific question is whether that balance produces useful metabolic effects without creating unacceptable tolerability or safety tradeoffs. How Retatrutide's Triple-Receptor Mechanism Differs Retatrutide activates the same GLP-1 and glucagon receptors while also activating the GIP receptor. GIP is an incretin signal involved in glucose-dependent insulin secretion and broader nutrient-response biology. The added GIP arm is the clearest mechanistic difference between retatrutide and survodutide. Triple agonism should not be reduced to a simple receptor count. The relative activity at each receptor, molecular design, exposure, trial population, and endpoint all matter. Readers comparing other multi-agonist designs can use our mazdutide vs tirzepatide vs retatrutide comparison to see how dual and triple receptor strategies differ across the wider pipeline. What the Clinical-Trial Evidence Shows Survodutide's Phase 3 SYNCHRONIZE-1 trial studied adults with obesity or overweight and an obesity-related complication, without diabetes. Published 2026 results reported significantly greater weight reduction than placebo over 76 weeks. Earlier Phase 2 obesity research also showed a dose-related effect, supporting advancement into the larger Phase 3 program. Retatrutide's Phase 2 obesity trial reported mean weight reduction of up to 24.2% at 48 weeks. Its 2026 Phase 3 TRIUMPH-1 readout reported up to 28.3% at 80 weeks under the efficacy estimand, and additional TRIUMPH readouts examined populations with type 2 diabetes, cardiovascular disease, and knee osteoarthritis. Some retatrutide results were still available as company-reported or conference data rather than fully published peer-reviewed reports at the time of this update, which limits how confidently details can be compared. Why the Trial Percentages Are Not a Head-to-Head Result It is tempting to place the largest reported percentage from each program in one table and declare a winner. That would be misleading. SYNCHRONIZE and TRIUMPH used different eligibility criteria, study durations, participant characteristics, dose-escalation designs, estimands, placebo responses, and rules for treatment discontinuation or missing data. The correct interpretation is narrower: each compound produced statistically meaningful results against its own placebo group in its own study. A higher number in one program does not isolate the contribution of GIP receptor activity, prove superior safety, or predict how the compounds would perform in the same participants. Only a randomized head-to-head trial could answer that comparative question directly. MASH and Liver-Research Context Survodutide has a distinct liver-focused evidence base. In a 48-week Phase 2 trial involving biopsy-confirmed metabolic dysfunction-associated steatohepatitis, or MASH, the primary histology endpoint was improvement in MASH without worsening of fibrosis. The study also evaluated liver-fat reduction and fibrosis improvement, establishing a rationale for further liver-specific research. The Phase 3 SYNCHRONIZE-MASLD trial then evaluated adults with obesity and at-risk metabolic dysfunction-associated steatotic liver disease, or MASLD, and reported reductions in liver fat and body weight after 48 weeks. Retatrutide also has liver-related research in its development program, but the publicly available record is not equivalent to survodutide's dedicated, published MASH/MASLD sequence. That difference is about evidence depth in a specific research area, not a treatment recommendation. Safety and Tolerability Limitations Gastrointestinal adverse events were common across both programs. Survodutide studies reported nausea, diarrhea, and vomiting among the recurring events, with the Phase 3 obesity trial describing gastrointestinal symptoms as mostly mild to moderate. Retatrutide trials likewise reported primarily gastrointestinal adverse events, with tolerability and discontinuation varying across study groups. Each mechanism also leaves compound-specific questions. Retatrutide's Phase 2 program observed dose-dependent heart-rate increases that peaked during the study and later declined. Glucagon-receptor agonism in both compounds makes cardiovascular, glycemic, hepatic, and metabolic monitoring important within formal trials. Short-to-medium-term trial findings cannot establish long-term safety, rare-event risk, or safety outside controlled research settings. FDA Status and Investigational Availability As of August 2026, neither survodutide nor retatrutide is FDA-approved. Both are investigational compounds. Positive trial results, completed Phase 3 studies, conference presentations, or a company's stated submission plans do not equal regulatory approval, and they do not create an approved indication. Products sold online under these compound names are not FDA-approved versions of the developers' investigational drugs. Their identity, purity, quantity, sterility, and manufacturing controls cannot be inferred from the clinical programs. PeptideStack does not recommend purchasing or using either compound and does not present research-vial listings as substitutes for regulated clinical-trial material. What Researchers Can and Cannot Conclude Researchers can conclude that survodutide and retatrutide represent different multi-receptor strategies, that both have progressed through large clinical programs, and that survodutide has a notably developed liver-specific evidence track. They can also conclude that receptor breadth alone does not explain every observed outcome. Researchers cannot conclude that one is universally more effective, safer, or more appropriate for an individual. Cross-trial percentages are descriptive, not comparative proof. For another example of why mechanism and evidence maturity need to be separated, see our CagriSema vs retatrutide comparison . Bottom Line: The Key Difference Is GIP, but the Evidence Is Broader The shortest answer is that survodutide is a GLP-1/glucagon dual agonist and retatrutide is a GLP-1/GIP/glucagon triple agonist. The fuller answer is that the programs also differ in trial design, evidence maturity, studied populations, and liver-research emphasis. Survodutide's dedicated MASH and MASLD work is a meaningful distinction, while retatrutide's broader triple-receptor program has produced substantial obesity-trial results. No direct trial has compared the two compounds, and neither has FDA approval. The responsible use of the evidence is to describe what each program tested and where uncertainty remains—not to convert separate trial results into medical guidance or a product ranking. Research-use-only disclaimer: This article is for informational and educational research context only. Survodutide and retatrutide are investigational and are not FDA-approved for human use. This content is not medical advice, does not provide dosing or treatment instructions, and does not recommend any product. PeptideStack does not sell, prescribe, manufacture, distribute, or fulfill these compounds. PeptideStack page context: visitors can use the header navigation to reach the product catalog, blog, calculators, supplier pages, discount-code pages, contact page, legal policies, privacy policy, terms, and research disclaimer. The site is organized around research peptide education, supplier transparency, product comparison, vendor review content, discount-code tracking, and calculator tools for reconstitution or unit conversion research planning. PeptideStack separates research-use-only peptide information from FDA-approved medication and licensed telehealth pathways. Research peptide pages are informational and are not medical advice, prescription guidance, dosing instructions, treatment recommendations, or instructions for human consumption. Many pages include affiliate disclosures because PeptideStack may earn a commission when visitors click external supplier or telehealth links. That commission does not change the price paid by visitors and does not mean PeptideStack manufactures, sells, distributes, compounds, or ships peptides or medications. Supplier and product pages should be evaluated for third-party testing, batch-specific certificates of analysis, named laboratory verification, transparent pricing, realistic delivery expectations, payment security, refund policies, support quality, and consistent research-use-only labeling. Blog pages connect related guides, comparison articles, FDA approval status explainers, safety context, legality resources, product pages, vendor reviews, and calculator tools so visitors can keep researching without relying on a single supplier claim. Calculator pages are educational tools for laboratory planning and should be cross-checked against professional protocols, institutional requirements, and applicable laws. Legal and disclaimer pages explain the boundaries of PeptideStack content and the responsibility of visitors who evaluate third-party vendors. The rendered interface may add interactive details such as mobile navigation labels, product tabs, share buttons, related article cards, disclosure boxes, call-to-action buttons, vendor selectors, copy-code controls, email-code forms, footer navigation, and status labels. The static HTML fallback includes this context so the same page purpose is understandable before the JavaScript application finishes loading. Visitors should treat PeptideStack as a research and comparison starting point. Final supplier evaluation should include direct review of the external vendor website, current product availability, checkout terms, applicable laws, institutional requirements, and any third-party laboratory documentation available for the exact product or batch being considered. Footer resources repeat important sitewide context: PeptideStack is independent, affiliate-supported, research-focused, and not a pharmacy or manufacturer. Pages may include links to the iOS app, calculators, blog hubs, product hubs, supplier comparisons, support contact, and policy documents. This repeated context is intentionally available in the raw HTML for crawlers that inspect a page before executing the React bundle. Raw HTML also includes page summaries for mobile crawlers using JavaScript rendering, desktop crawlers comparing source to rendered output, accessibility tools, and no-script visitors. The fallback is replaced by the React app in normal browsers but keeps the source document aligned with the visible page topic. This fallback keeps source HTML and rendered HTML closer for crawl diagnostics and SEO audits across crawled pages, routes, reports, and recrawls.